fasudil has been researched along with Subarachnoid Hemorrhage in 44 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 9.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 9.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "This study aims to systematically assess the efficacy and safety of fasudil for the treatment of aneurysmal subarachnoid hemorrhage (ASH)." | 9.01 | Efficacy of fasudil for the treatment of aneurysmal subarachnoid hemorrhage: A systematic review protocol of randomized controlled trial. ( Chang, XF; Shen, RB; Song, GF; Wang, HY; Yang, FY; Yang, HW, 2019) |
| " To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH)." | 8.90 | Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies. ( Asano, T; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M, 2014) |
| "Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale)." | 8.88 | Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. ( He, GH; Liu, GJ; Liu, Y; Luo, GJ; Wang, XL; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ, 2012) |
| "The incidence of convulsion and associated factors were retrospectively analyzed in 23 patients with symptomatic cerebral vasospasm following subarachnoid hemorrhage (SAH) who underwent a total of 31 intra-arterial infusion of fasudil hydrochloride (IAFH) procedures in 49 vessels." | 7.76 | Convulsion during intra-arterial infusion of fasudil hydrochloride for the treatment of cerebral vasospasm following subarachnoid hemorrhage. ( Enomoto, Y; Iwama, T; Yamada, K; Yoshimura, S, 2010) |
| "The cerebral circulatory dynamics were evaluated before and after intra-arterial administration of fasudil hydrochloride in 20 patients with angiographic vasospasm after subarachnoid hemorrhage (SAH)." | 7.73 | Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography. ( Hayashi, M; Iwabuchi, S; Samejima, H; Ueda, M; Uehara, H; Yokouchi, T, 2006) |
| "The authors report a case of convulsion during intra-arterial selective infusion of fasudil hydrochloride (FSD) for treatment of vasospasm following subarachnoid hemorrhage (SAH)." | 7.72 | [A case of convulsion during selective intra-arterial infusion of fasudil hydrochloride for treatment of vasospasm following subarachnoid hemorrhage]. ( Date, I; Nakashimia, H; Ohmoto, T; Ono, S; Sasahara, W; Sugiu, K; Tokunaga, K, 2004) |
| "To investigate the safety and efficacy of liposomal fasudil in a sustained-release form for the prevention of cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 7.71 | Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. ( Ishida, T; Kiwada, H; Meguro, T; Takanashi, Y; Yamamoto, I; Zhang, JH, 2001) |
| " Since September 1995, the combination of fasudil hydrochloride and ozagrel sodium, an inhibitor of thromboxane A2 synthesis, has been used to treat 60 patients at risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage." | 7.70 | Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. ( Abe, M; Fukuyama, K; Mineta, T; Nakashima, S; Shimokawa, S; Tabuchi, K, 1998) |
| "Fasudil were added in 18 (38." | 5.91 | Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. ( Araki, Y; Asai, T; Fukui, T; Koketsu, N; Muraoka, S; Nishizawa, T; Ota, S; Saito, R; Shimato, S, 2023) |
| " The occurrence of adverse events, occurrence of low density areas associated with vasospasm on computed tomography, absence of symptomatic vasospasm, and poor clinical outcomes associated with vasospasm were compared between the fasudil and fasudil plus ozagrel groups." | 5.35 | Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. ( Satoh, S; Seto, M; Shibuya, M; Sugiyama, H; Suzuki, Y; Takakura, K, 2008) |
| "This new approach for cerebral vasospasm may have significant potential for use in the clinical setting." | 5.31 | Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Meguro, T; Takanashi, Y; Zhang, JH, 2001) |
| "since October 1999, nicardipine pellets (NP) have been used to prevent vasospasm in patients with subarachnoid hemorrhage (SAH)." | 5.15 | Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo. ( Kasuya, H, 2011) |
| "Fasudil is believed to be at least equally effective as nimodipine for the prevention of cerebral vasospasm and subsequent ischemic injury in patients undergoing surgery for subarachnoid hemorrhage (SAH)." | 5.15 | Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. ( Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011) |
| " This randomized open trial with nimodipine as the control included 72 patients who underwent subarachnoid hemorrhage surgery for ruptured cerebral aneurysm of Hunt and Hess grades I to IV." | 5.12 | Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. ( Guo, J; Ren, Z; Wang, R; Wang, S; Xu, B; Zhao, J; Zhou, D; Zhou, L, 2006) |
| "This study aims to systematically assess the efficacy and safety of fasudil for the treatment of aneurysmal subarachnoid hemorrhage (ASH)." | 5.01 | Efficacy of fasudil for the treatment of aneurysmal subarachnoid hemorrhage: A systematic review protocol of randomized controlled trial. ( Chang, XF; Shen, RB; Song, GF; Wang, HY; Yang, FY; Yang, HW, 2019) |
| " To date, the only Rho-kinase inhibitor employed clinically in humans is fasudil, which has been used for the prevention of cerebral vasospasm and subsequent ischemic injury after surgery for subarachnoid hemorrhage (SAH)." | 4.90 | Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies. ( Asano, T; Ikegaki, I; Kawasaki, K; Satoh, S; Shibuya, M, 2014) |
| "Fasudil greatly reduces the occurrence of CVS and cerebral infarction in SAH patients, significantly improves the clinical outcomes of the patients (as assessed by the Glasgow Outcome Scale)." | 4.88 | Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. ( He, GH; Liu, GJ; Liu, Y; Luo, GJ; Wang, XL; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ, 2012) |
| "We envisage the efficacy and safety of intra-arterial infusion of fasudil hydrochloride (IAF) for symptomatic vasospasm (SVS) after subarachnoid hemorrhage (SAH)." | 3.79 | Beneficial effect of selective intra-arterial infusion of fasudil hydrochloride as a treatment of symptomatic vasospasm following SAH. ( Chang, HS; Fujisawa, N; Hosono, A; Indo, M; Matsui, T; Nakamura, T; Okano, A; Oya, S; Suzuki, Y; Tsuchiya, T, 2013) |
| "The incidence of convulsion and associated factors were retrospectively analyzed in 23 patients with symptomatic cerebral vasospasm following subarachnoid hemorrhage (SAH) who underwent a total of 31 intra-arterial infusion of fasudil hydrochloride (IAFH) procedures in 49 vessels." | 3.76 | Convulsion during intra-arterial infusion of fasudil hydrochloride for the treatment of cerebral vasospasm following subarachnoid hemorrhage. ( Enomoto, Y; Iwama, T; Yamada, K; Yoshimura, S, 2010) |
| "Using CT perfusion studies we evaluated changes in the cerebral circulation before and after the intravenous administration of fasudil 60 mg in 8 patients 7 to 14 days after a subarachnoid hemorrhage." | 3.73 | [Cerebral circulation dynamics following fasudil intravenous infusion: a CT perfusion study]. ( Ono, K; Shirotani, T; Yamana, D; Yuba, K, 2005) |
| "The cerebral circulatory dynamics were evaluated before and after intra-arterial administration of fasudil hydrochloride in 20 patients with angiographic vasospasm after subarachnoid hemorrhage (SAH)." | 3.73 | Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography. ( Hayashi, M; Iwabuchi, S; Samejima, H; Ueda, M; Uehara, H; Yokouchi, T, 2006) |
| "The authors report a case of convulsion during intra-arterial selective infusion of fasudil hydrochloride (FSD) for treatment of vasospasm following subarachnoid hemorrhage (SAH)." | 3.72 | [A case of convulsion during selective intra-arterial infusion of fasudil hydrochloride for treatment of vasospasm following subarachnoid hemorrhage]. ( Date, I; Nakashimia, H; Ohmoto, T; Ono, S; Sasahara, W; Sugiu, K; Tokunaga, K, 2004) |
| "To investigate the safety and efficacy of liposomal fasudil in a sustained-release form for the prevention of cerebral vasospasm after subarachnoid hemorrhage (SAH)." | 3.71 | Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage. ( Ishida, T; Kiwada, H; Meguro, T; Takanashi, Y; Yamamoto, I; Zhang, JH, 2001) |
| " Since September 1995, the combination of fasudil hydrochloride and ozagrel sodium, an inhibitor of thromboxane A2 synthesis, has been used to treat 60 patients at risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage." | 3.70 | Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. ( Abe, M; Fukuyama, K; Mineta, T; Nakashima, S; Shimokawa, S; Tabuchi, K, 1998) |
| "The chapter on subarachnoid hemorrhage includes new and revised recommendations for diagnosis, treatment selection, and management of vasospasm." | 2.53 | [Japanese Guidelines for the Management of Stroke 2015: overview of the chapter on Subarachnoid Hemorrhage]. ( Ishihara, H; Suzuki, M, 2016) |
| "Fasudil were added in 18 (38." | 1.91 | Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. ( Araki, Y; Asai, T; Fukui, T; Koketsu, N; Muraoka, S; Nishizawa, T; Ota, S; Saito, R; Shimato, S, 2023) |
| " The occurrence of adverse events, occurrence of low density areas associated with vasospasm on computed tomography, absence of symptomatic vasospasm, and poor clinical outcomes associated with vasospasm were compared between the fasudil and fasudil plus ozagrel groups." | 1.35 | Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. ( Satoh, S; Seto, M; Shibuya, M; Sugiyama, H; Suzuki, Y; Takakura, K, 2008) |
| "Fasudil hydrochloride was administered via the internal carotid artery without selective microcatheterization, at a concentration and speed of 30 mg/20 ml/10-15 min, using a total dose of 30-60 mg." | 1.33 | [Intra-arterial administration of fasudil hydrochloride: duration of action]. ( Matsushita, Y; Ono, K; Shirotani, T; Takahara, T; Wada, K; Yamana, D; Yuba, K, 2005) |
| "Delayed cerebral vasospasm after subarachnoid hemorrhage (SAH) may be due, in part, to altered regulation of arterial smooth muscle contraction." | 1.33 | Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage. ( Faraci, FM; Heistad, DD; Watanabe, Y, 2005) |
| "Cerebral vasospasm is a potentially fatal consequence of aneurysmal subarachnoid hemorrhage and influences the prognosis of the patient." | 1.31 | Thin and thick filament regulation of contractility in experimental cerebral vasospasm. ( Butler, WE; Kim, I; Leinweber, BD; Morgalla, M; Morgan, KG; Peterson, JW; Sasaki, Y; Seto, M, 2000) |
| "This new approach for cerebral vasospasm may have significant potential for use in the clinical setting." | 1.31 | Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats. ( Allen, TM; Ishida, T; Kirchmeier, MJ; Meguro, T; Takanashi, Y; Zhang, JH, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.55) | 18.7374 |
| 1990's | 8 (18.18) | 18.2507 |
| 2000's | 16 (36.36) | 29.6817 |
| 2010's | 16 (36.36) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Muraoka, S | 1 |
| Asai, T | 1 |
| Fukui, T | 1 |
| Ota, S | 1 |
| Shimato, S | 1 |
| Koketsu, N | 1 |
| Nishizawa, T | 1 |
| Araki, Y | 1 |
| Saito, R | 1 |
| Ohta, T | 1 |
| Matsumoto, S | 1 |
| Fukumitsu, R | 1 |
| Imamura, H | 1 |
| Adachi, H | 1 |
| Hara, Y | 1 |
| Hosoda, K | 1 |
| Kimura, H | 3 |
| Kuwayama, K | 1 |
| Mizowaki, T | 1 |
| Motooka, Y | 1 |
| Miyata, S | 1 |
| Shinoda, N | 1 |
| Ueno, Y | 1 |
| Yamaura, I | 1 |
| Yoshida, Y | 1 |
| Sakai, C | 1 |
| Sakai, N | 1 |
| Wang, HY | 1 |
| Song, GF | 1 |
| Yang, HW | 1 |
| Chang, XF | 1 |
| Shen, RB | 1 |
| Yang, FY | 1 |
| Fan, R | 1 |
| Enkhjargal, B | 1 |
| Camara, R | 1 |
| Yan, F | 1 |
| Gong, L | 1 |
| Tang, J | 1 |
| Chen, Y | 1 |
| Zhang, JH | 4 |
| Naraoka, M | 2 |
| Munakata, A | 1 |
| Matsuda, N | 1 |
| Shimamura, N | 2 |
| Ohkuma, H | 2 |
| Satoh, S | 6 |
| Ikegaki, I | 4 |
| Kawasaki, K | 1 |
| Asano, T | 5 |
| Shibuya, M | 10 |
| Iwabuchi, S | 3 |
| Hayashi, M | 3 |
| Yokouchi, T | 3 |
| Sato, K | 2 |
| Nakayama, H | 2 |
| Harashina, J | 2 |
| Iwama, J | 1 |
| Ishii, M | 1 |
| Hiramoto, Y | 1 |
| Hirai, N | 1 |
| Hirata, Y | 2 |
| Saito, N | 2 |
| Ito, K | 2 |
| Aoki, K | 2 |
| Saito, A | 1 |
| Inoue, M | 1 |
| Kon, H | 1 |
| Imaruoka, S | 1 |
| Basaki, K | 1 |
| Midorikawa, H | 1 |
| Sasaki, T | 3 |
| Nishijima, M | 1 |
| Egea-Guerrero, JJ | 1 |
| Murillo-Cabezas, F | 1 |
| Muñoz-Sánchez, MÁ | 1 |
| Vilches-Arenas, A | 1 |
| Porras-González, C | 1 |
| Castellano, A | 1 |
| Ureña, J | 1 |
| González-Montelongo, Mdel C | 1 |
| Ishihara, H | 1 |
| Suzuki, M | 1 |
| Suzuki, Y | 10 |
| Sugiyama, H | 1 |
| Seto, M | 2 |
| Takakura, K | 4 |
| Nakano, T | 1 |
| Ogasawara, Y | 1 |
| Takeda, T | 1 |
| Enomoto, Y | 1 |
| Yoshimura, S | 1 |
| Yamada, K | 1 |
| Iwama, T | 1 |
| Pierot, L | 1 |
| Aggour, M | 1 |
| Moret, J | 1 |
| Kasuya, H | 1 |
| Akahata, M | 1 |
| Ishihara, M | 1 |
| Yamanaka, K | 1 |
| Nakajima, S | 1 |
| Yamasaki, M | 1 |
| Liu, GJ | 1 |
| Wang, ZJ | 1 |
| Wang, YF | 1 |
| Xu, LL | 1 |
| Wang, XL | 1 |
| Liu, Y | 1 |
| Luo, GJ | 1 |
| He, GH | 1 |
| Zeng, YJ | 1 |
| Zhao, J | 2 |
| Zhou, D | 2 |
| Guo, J | 2 |
| Ren, Z | 2 |
| Zhou, L | 2 |
| Wang, S | 2 |
| Zhang, Y | 1 |
| Xu, B | 3 |
| Zhao, K | 1 |
| Wang, R | 2 |
| Mao, Y | 1 |
| Zhang, X | 1 |
| Nakamura, T | 1 |
| Matsui, T | 1 |
| Hosono, A | 1 |
| Okano, A | 1 |
| Fujisawa, N | 1 |
| Tsuchiya, T | 1 |
| Indo, M | 1 |
| Oya, S | 1 |
| Chang, HS | 1 |
| Sasahara, W | 1 |
| Ono, S | 1 |
| Tokunaga, K | 1 |
| Sugiu, K | 1 |
| Nakashimia, H | 1 |
| Date, I | 1 |
| Ohmoto, T | 1 |
| Watanabe, Y | 1 |
| Faraci, FM | 1 |
| Heistad, DD | 1 |
| Ono, K | 2 |
| Shirotani, T | 2 |
| Wada, K | 1 |
| Takahara, T | 1 |
| Matsushita, Y | 1 |
| Yuba, K | 2 |
| Yamana, D | 2 |
| Fuse, T | 1 |
| Umezu, M | 1 |
| Yamamoto, M | 1 |
| Demura, K | 1 |
| Nishikawa, Y | 1 |
| Niwa, Y | 1 |
| Uehara, H | 1 |
| Ueda, M | 1 |
| Samejima, H | 1 |
| Sugimoto, Y | 1 |
| Duan, WG | 1 |
| Yuan, ST | 1 |
| Liao, H | 1 |
| Yan, M | 1 |
| Zhang, LY | 1 |
| Nishizawa, S | 1 |
| Shiota, T | 1 |
| Bernanke, DH | 1 |
| Parent, AD | 1 |
| Hasui, K | 1 |
| Feigin, VL | 1 |
| Rinkel, GJ | 1 |
| Algra, A | 1 |
| Vermeulen, M | 1 |
| van Gijn, J | 1 |
| Nakashima, S | 1 |
| Tabuchi, K | 1 |
| Shimokawa, S | 1 |
| Fukuyama, K | 1 |
| Mineta, T | 1 |
| Abe, M | 1 |
| Tachibana, E | 1 |
| Harada, T | 3 |
| Saito, K | 1 |
| Takayasu, M | 3 |
| Yoshida, J | 1 |
| Kim, I | 1 |
| Leinweber, BD | 1 |
| Morgalla, M | 1 |
| Butler, WE | 1 |
| Sasaki, Y | 1 |
| Peterson, JW | 1 |
| Morgan, KG | 1 |
| Takanashi, Y | 2 |
| Ishida, T | 2 |
| Meguro, T | 2 |
| Kiwada, H | 1 |
| Yamamoto, I | 1 |
| Masaoka, H | 1 |
| Takasato, Y | 1 |
| Nojiri, T | 1 |
| Hayakawa, T | 1 |
| Akimoto, H | 1 |
| Yatsushige, H | 1 |
| Toumori, H | 1 |
| Miyazaki, Y | 1 |
| Honma, M | 1 |
| Kirchmeier, MJ | 1 |
| Allen, TM | 1 |
| Sugita, K | 4 |
| Hidaka, H | 6 |
| Saito, I | 2 |
| Nagata, I | 1 |
| Kikuchi, H | 2 |
| Takemae, T | 2 |
| Okamoto, S | 1 |
| Kanamori, M | 1 |
| Okada, T | 1 |
| Kageyama, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study[NCT01996436] | Phase 4 | 330 participants (Anticipated) | Interventional | 2016-08-29 | Recruiting | ||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Efficacy and Safety of Cilostazol-Nimodipine Combined Therapy on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial[NCT04148105] | Phase 4 | 120 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for fasudil and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Efficacy of fasudil for the treatment of aneurysmal subarachnoid hemorrhage: A systematic review protocol of randomized controlled trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Humans; Intracranial Aneurysm; Randomized Controlled | 2019 |
Pleiotropic effects of the rho-kinase inhibitor fasudil after subarachnoid hemorrhage: a review of preclinical and clinical studies.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Clinical Trials as Topic; Dr | 2014 |
[Japanese Guidelines for the Management of Stroke 2015: overview of the chapter on Subarachnoid Hemorrhage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antifibrinolytic Agents; Endovascular Procedures; Hum | 2016 |
Vasospasm after aneurysmal subarachnoid hemorrhage: recent advances in endovascular management.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angioplasty, Balloon; Critical Care; Endovascular Pro | 2010 |
Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Cerebral Infarction; Humans; Middle Aged; Prot | 2012 |
[Advances in the study of Rho kinase and its inhibitors].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antihypertensive Agents; Cardiovascular Disea | 2007 |
[Basic research and treatment for cerebral vasospasm after subarachnoid hemorrhage: the present and future prospects].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Angioplasty, Balloon; Calcium Channel | 2008 |
Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Humans; Intracranial Aneury | 1998 |
7 trials available for fasudil and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Calcium Channel Blockers; Cooperative Be | 2011 |
Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain Ischemia; Calcium Channel Blockers | 2011 |
Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Brain Ischemia; Female; Humans; Male; Middle A | 2006 |
A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Aged; Cohort Studies; Female; Huma | 2007 |
Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aneurysm, Ruptured; Female; Humans; Infu | 1999 |
Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Calcium; Cerebral Infarction; Double-Bli | 1992 |
Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Blood Pressure; Calcium Channel Blockers | 1990 |
29 other studies available for fasudil and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Real-world data of clazosentan in combination therapy for aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study.
Topics: Aged; Brain Ischemia; Cerebral Infarction; Female; Humans; Middle Aged; Retrospective Studies; Subar | 2023 |
Incidence and Outcomes of Aneurysmal Subarachnoid Hemorrhage: A Multicenter Retrospective Registry-based Descriptive Trial in Kobe City.
Topics: Humans; Incidence; Prognosis; Retrospective Studies; Subarachnoid Hemorrhage; Treatment Outcome; Vas | 2023 |
Critical role of EphA4 in early brain injury after subarachnoid hemorrhage in rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood-Brain Barrier; Brain; Brain Edema; Bra | 2017 |
Suppression of the Rho/Rho-kinase pathway and prevention of cerebral vasospasm by combination treatment with statin and fasudil after subarachnoid hemorrhage in rabbit.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Drug Combinations; Enzyme-Li | 2013 |
Prophylactic intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid haemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Combined Modality The | 2015 |
Effectiveness of intraarterial administration of fasudil hydrochloride for preventing symptomatic vasospasm after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiography, Digital Subtraction; Blood Circulation T | 2015 |
Role of L-type Ca(2+) channels, sarcoplasmic reticulum and Rho kinase in rat basilar artery contractile properties in a new model of subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Calcium; Calcium Channel Blo | 2015 |
Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Drug Therapy, Combination; Enzyme Inhibitors; F | 2008 |
[Role of coil embolization and arterial injection in elderly subarachnoid hemorrhage patients: preliminary report].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Aged, 80 and over; Anesthesia, Local; Embolizat | 2008 |
Convulsion during intra-arterial infusion of fasudil hydrochloride for the treatment of cerebral vasospasm following subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cath | 2010 |
Intra-arterial Administration of Fasudil Hydrochloride for Vasospasm Following Subarachnoid Haemorrhage: Experience of 90 Cases.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Calcium Channel Blockers; Cerebral Angiography; Femal | 2011 |
Intracranial hemorrhage after intra-arterial administration of fasudil for treatment of cerebral vasospasm following subarachnoid hemorrhage: a serious adverse event.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Cerebral Angiography; Embolization, Therapeutic; Fata | 2012 |
Beneficial effect of selective intra-arterial infusion of fasudil hydrochloride as a treatment of symptomatic vasospasm following SAH.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Coronary Angiography; Coronary Vasospasm | 2013 |
[A case of convulsion during selective intra-arterial infusion of fasudil hydrochloride for treatment of vasospasm following subarachnoid hemorrhage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; | 2004 |
Activation of Rho-associated kinase during augmented contraction of the basilar artery to serotonin after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Disease Models, Animal; Enzy | 2005 |
[Intra-arterial administration of fasudil hydrochloride: duration of action].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Carotid Artery, Internal; Cerebral Arteries; Ce | 2005 |
[Cerebral circulation dynamics following fasudil intravenous infusion: a CT perfusion study].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Brain; Cerebrovascular Circulation; Fema | 2005 |
External carotid artery aneurysm developing after embolization of a ruptured posterior inferior cerebellar artery aneurysm in a patient with cervicocephalic fibromuscular dysplasia--case report.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aneurysm, Ruptured; Angiography, Digital Subtr | 2006 |
Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage - analysis of time-density curve with digital subtraction angiography.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Angiography, Digital Subtraction; Brain; | 2006 |
Protein kinase C has two different major roles in lattice compaction enhanced by cerebrospinal fluid from patients with subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenylyl Cyclases; Cerebrospinal Fluid; Colforsin; Di | 1996 |
Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aneurysm, Ruptured; Calcium Channel Bloc | 1998 |
Thin and thick filament regulation of contractility in experimental cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Basilar Artery; Calcium-Binding Prot | 2000 |
Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm after subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Dogs; Dose-Response Relation | 2001 |
Clinical effect of Fasudil hydrochloride for cerebral vasospasm following subarachnoid hemorrhage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Aged, 80 and over; Cerebral Angiography; | 2001 |
Intrathecal application with liposome-entrapped Fasudil for cerebral vasospasm following subarachnoid hemorrhage in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Drug Delivery Systems; Injec | 2001 |
Possible prophylactic potential of HA1077, a Ca2+ channel antagonist and vasodilator, on chronic cerebral vasospasm.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Calcium; Cerebrovascular Cir | 1992 |
The effects of HA1077 on the cerebral circulation after subarachnoid haemorrhage in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Flow Velocity; Blood Volume; Brain; Ca | 1991 |
The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Calcium Channel Blockers; Cerebral | 1988 |
The effects of HA compound calcium antagonists on delayed cerebral vasospasm in dogs.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Basilar Artery; Calcium Channel Blockers; Ch | 1986 |